<HTML>
<head><title>8-K EastGate May 4, 2018</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; MARGIN-TOP:0px; COLOR:#000000"> <div align=center> <div style=WIDTH:576px> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>UNITED STATES</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>SECURITIES AND EXCHANGE COMMISSION</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>Washington, DC 20549</b></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>FORM 8-K</b></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>CURRENT REPORT</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>Pursuant to Section 13 or 15(d) of the</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>Securities Exchange Act of 1934</b></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=left>Date of report (Date of earliest event reported): &nbsp;<u>April 20, 2018</u></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=left>Commission File Number: &nbsp;<u>00052886</u></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:18pt; MARGIN:0px" align=center><b>EASTGATE BIOTECH CORP.</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(Exact name of small business issuer as specified in its charter)</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><u>Nevada</u></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(State or other jurisdiction of incorporation or organization)</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><u>87-0639378 </u></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(IRS Employer Identification No.)</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:14.5pt; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:14.5pt; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>2203-65 Harbour Square | Toronto, Ontario | Canada M5J 2L4</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(Address of principal executive offices)</p> <p style="FONT-SIZE:14.5pt; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>(647) 692-0652</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(Registrant's Telephone number)</p> <p style="FONT-SIZE:14.5pt; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><u>__________________________</u></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(Former Name or Former Address, if Changed Since Last Report)</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=left>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=left>[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style=MARGIN:0px align=left><br></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; PAGE-BREAK-BEFORE:always; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=left>[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=left>[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px" align=left>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=left>[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p> <p style=MARGIN:0px align=left><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify><b><u>Item 1.01 &nbsp;Entry Into a Material Definitive Agreement</u></b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>On April 20, 2018, EastGate Biotech Corp. (the <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>) issued a $450,000 (the <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>Note<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>). &nbsp;&nbsp;The Note shall be due on July 20, 2018, or such later date as may be negotiated by the parties in good faith. &nbsp;The Note does not bear interest and may be convertible into common stock of the Company prior to maturity at a conversion price as may be negotiated by the parties in good faith. &nbsp;The holder has the right to demand repayment of $150,000 of the principal 60 days after the issuance date. &nbsp;Following a default and lapse of a ten-business day cure period, the holder shall have the option to convert all amounts due under the note at an 80% discount to the volume weighted average price of the common stock during the cure period.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>In connection with the Note, the Company issued to the lender warrants to purchase an aggregate of 45,000,000 shares of its common stock, consisting of (i) a warrant to purchase 9,000,000 shares to be issued on each of May 20, 2018, June 20, 2018, and July 20, 2019 (collectively the <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>Series A Warrants<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>) and (ii) a Warrant to purchase 18,000,000 shares to be issued on the Maturity Date (the <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>Series B Warrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>) and, together with the Series A Warrants, the <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>Warrants<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>). &nbsp;The Series A Warrants shall have an exercise price of $0.0045 per share and the Series B Warrants shall have an exercise price equal to a 30% premium to the closing price of the common stock on the Maturity Date.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>The Principal Amount of $450,000 outstanding at any time, and from time to time, under this Note shall bear no interest. &nbsp;</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>The Company agrees to issue Warrants to the Lender (or as directed by the Lender) as part of the Borrower<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s Obligations. &nbsp;The schedule of warrants issued will be: (i) Nine (9) million warrants to be issued at the end of 30 days from the receipt of Principal Amount, and every 30 days thereafter until the Maturity Date, (ii) Warrants mentioned in (i) will grant the Lender, if exercised in part or in full, twenty seven (27) million common stock at $0.0045 per share, (iii) Further to the warrants issued from part (i), an additional eighteen (18) million common stock purchase warrants will be issued on the Maturity Date, which will allow the Lender, if </p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; PAGE-BREAK-BEFORE:always; MARGIN:0px" align=justify>exercised, in part or in full, to purchase 18,000,000 common stock at a thirty (30) percent premium on the closing bid purchase price on the Maturity Date.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>The foregoing descriptions of the Note, Series A Warrants and Series B Warrant are not complete and are qualified in their entireties by reference to the full text of the form of Note, the form of Series A Warrant and Form of Series B Warrant, copies of which are filed as Exhibit 10.1, Exhibit 10.2 and Exhibit 10.3, respectively, to this Report and are incorporated by reference herein.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>The proceeds from the note shall be used for potential corporate transaction and general working capital.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify><b><u>Item 3.02 Unregistered Sales of Equity Securities.</u></b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>Reference is made to the disclosure set forth under Item 1.01 above, which is incorporated by reference, in its entirety, into this Item 3.02.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>The Note, Warrants and shares of common stock issuable upon conversion of the Note and exercise of the Warrants have not been registered under the Securities Act of 1933, as amended (the <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>Securities Act<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>), or the securities laws of any state, and were offered and issued in reliance on the exemption from registration under the Securities Act, afforded by Section 4 (a)(2) promulgated under the Securities Act.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify><b><u>Item 9.01 &nbsp;Exhibits.</u></b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>(d) Exhibits.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>10.1 &nbsp;Form of Note</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>10.2 &nbsp;Form of Series A Warrant</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>10.3 &nbsp;Form of Series B Warrant</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(Signature Page Follows)</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; PAGE-BREAK-BEFORE:always; MARGIN:0px" align=justify><b>SIGNATURE</b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=left><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=left>EastGate Biotech Corp. </p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=left>(Registrant)</p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=left><br></p> <div align=left> <p style="FONT-SIZE:13pt; MARGIN-BOTTOM:-2px; WIDTH:240px; MARGIN-TOP:0px; FLOAT:left">Date: &nbsp;May 4, 2018 </p></div> <p style="FONT-SIZE:13pt; MARGIN:0px; TEXT-INDENT:-2px" align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By: /s/ Anna Gluskin</p> <p style="FONT-SIZE:13pt; CLEAR:left; MARGIN:0px" align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Chairman and Chief Executive Officer</p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=left><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br><br></p></div></div></body>
<!-- EDGAR Validation Code: FC1AEC82 -->
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "eastgatebiotech8kapril202018.htm", "description": "8-K EASTGATE MAY 4, 2018", "secsgml_size_bytes": 13746}]
{"company-data": {"conformed-name": "EASTGATE BIOTECH CORP", "cik": "0001099574", "assigned-sic": "6799", "irs-number": "870639378", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52886", "film-number": "18809490"}, "business-address": {"street1": "2681 EAST PARLEYS WAY - SUITE 204", "city": "SALT LAKE CITY", "state": "UT", "zip": "84109", "phone": "8013223401"}, "mail-address": {"street1": "2681 EAST PARLEYS WAY - SUITE 204", "city": "SALT LAKE CITY", "state": "UT", "zip": "84109"}, "former-company": {"former-conformed-name": "EASTGATE ACQUISITIONS CORP", "date-changed": "19991123"}}
8-K EastGate May 4, 2018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
April 20, 2018
Commission File Number:
00052886
EASTGATE BIOTECH CORP.
(Exact name of small business issuer as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or organization)
87-0639378
(IRS Employer Identification No.)
2203-65 Harbour Square | Toronto, Ontario | Canada M5J 2L4
(Address of principal executive offices)
(647) 692-0652
(Registrant's Telephone number)
__________________________
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01  Entry Into a Material Definitive Agreement
On April 20, 2018, EastGate Biotech Corp. (the
"
Company
"
) issued a $450,000 (the
"
Note
"
).   The Note shall be due on July 20, 2018, or such later date as may be negotiated by the parties in good faith.  The Note does not bear interest and may be convertible into common stock of the Company prior to maturity at a conversion price as may be negotiated by the parties in good faith.  The holder has the right to demand repayment of $150,000 of the principal 60 days after the issuance date.  Following a default and lapse of a ten-business day cure period, the holder shall have the option to convert all amounts due under the note at an 80% discount to the volume weighted average price of the common stock during the cure period.
In connection with the Note, the Company issued to the lender warrants to purchase an aggregate of 45,000,000 shares of its common stock, consisting of (i) a warrant to purchase 9,000,000 shares to be issued on each of May 20, 2018, June 20, 2018, and July 20, 2019 (collectively the
"
Series A Warrants
"
) and (ii) a Warrant to purchase 18,000,000 shares to be issued on the Maturity Date (the
"
Series B Warrant
"
) and, together with the Series A Warrants, the
"
Warrants
"
).  The Series A Warrants shall have an exercise price of $0.0045 per share and the Series B Warrants shall have an exercise price equal to a 30% premium to the closing price of the common stock on the Maturity Date.
The Principal Amount of $450,000 outstanding at any time, and from time to time, under this Note shall bear no interest.
The Company agrees to issue Warrants to the Lender (or as directed by the Lender) as part of the Borrower
'
s Obligations.  The schedule of warrants issued will be: (i) Nine (9) million warrants to be issued at the end of 30 days from the receipt of Principal Amount, and every 30 days thereafter until the Maturity Date, (ii) Warrants mentioned in (i) will grant the Lender, if exercised in part or in full, twenty seven (27) million common stock at $0.0045 per share, (iii) Further to the warrants issued from part (i), an additional eighteen (18) million common stock purchase warrants will be issued on the Maturity Date, which will allow the Lender, if
exercised, in part or in full, to purchase 18,000,000 common stock at a thirty (30) percent premium on the closing bid purchase price on the Maturity Date.
The foregoing descriptions of the Note, Series A Warrants and Series B Warrant are not complete and are qualified in their entireties by reference to the full text of the form of Note, the form of Series A Warrant and Form of Series B Warrant, copies of which are filed as Exhibit 10.1, Exhibit 10.2 and Exhibit 10.3, respectively, to this Report and are incorporated by reference herein.
The proceeds from the note shall be used for potential corporate transaction and general working capital.
Item 3.02 Unregistered Sales of Equity Securities.
Reference is made to the disclosure set forth under Item 1.01 above, which is incorporated by reference, in its entirety, into this Item 3.02.
The Note, Warrants and shares of common stock issuable upon conversion of the Note and exercise of the Warrants have not been registered under the Securities Act of 1933, as amended (the
"
Securities Act
"
), or the securities laws of any state, and were offered and issued in reliance on the exemption from registration under the Securities Act, afforded by Section 4 (a)(2) promulgated under the Securities Act.
Item 9.01  Exhibits.
(d) Exhibits.
10.1  Form of Note
10.2  Form of Series A Warrant
10.3  Form of Series B Warrant
(Signature Page Follows)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EastGate Biotech Corp.
(Registrant)
Date:  May 4, 2018
By: /s/ Anna Gluskin
Title: Chairman and Chief Executive Officer